B&B Tools AB

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 19 January 2009 - Galapagos NV (Euronext: GLPG) announced today that it has expanded the alliance in antibacterials and antivirals with GlaxoSmithKline (GSK) to include three more discovery targets. For this expansion, Galapagos receives a payment from GSK of €2 million cash.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 14 January 2009 - Galapagos NV (Euronext: GLPG) announced today achievement of multiple milestones under its alliance with Janssen Pharmaceutica NV ('Janssen'). Through the achievement of the milestone payments announced today Galapagos will receive a total of €3.75 million.

Galapagos NV (EBR:GLPG) * Galapagos to discover small molecule candidate drugs for pre-clinical development * Upfront fee, milestones on pre-clinical and clinical development of small molecule candidates, plus royalties on worldwide sales

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 5 January 2009 - Galapagos NV (Euronext: GLPG) announced today that it has successfully achieved a pre-clinical candidate drug in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached milestones on other compounds in the alliance, triggering payments totaling €7.6 million to Galapagos. To date, Galapagos has earned a total of €25.5 million in payments from GSK under this alliance.

Galapagos NV (EBR:GLPG) Mechelen, Belgium and Biocitech Park, Romainville, France; 5 January 2009 - Galapagos NV (Euronext: GLPG) announced today that it has selected a candidate drug to enter into pre-clinical development in the Company's cachexia (loss of weight and muscle mass) program. This candidate drug is a small molecule that Galapagos has developed in its Selective Androgen Receptor Modulator (SARM) program and which has demonstrated successful Proof of Concept in animal studies.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 30 December 2008 - Galapagos NV (Euronext: GLPG) announced that it has received transparency notifications from several major shareholders pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 22 December 2008 - Galapagos NV (Euronext: GLPG) announced today that it has expanded the osteoarthritis alliance with GlaxoSmithKline (GSK) to include two additional drug targets. For this expansion, Galapagos receives a payment from GSK of €2 million cash. This payment is in addition to the existing alliance terms, making the total alliance now worth up to €188 million. Including today's payment, Galapagos has received a total of €17.9 million in payments from GSK under this alliance.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 18 December 2008 - Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive €2.0 M ($2.55 M) in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.

Galapagos NV (EBR:GLPG) Mechelen, Belgium and San Diego, USA; 9 December 2008 - Galapagos NV (Euronext: GLPG) and Dart Neuroscience LLC (DNS) announced today new collaboration agreements in drug discovery and compound management. Total potential value of the contracts for Galapagos is €4.1 million (US$5.4 million) over three years.

Galapagos NV (EBR:GLPG) Combination of proprietary drug targets and unique technologies to create range of new therapeutic antibodies